Models, Mechanisms and Clinical Evidence for Cancer Dormancy

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2007 Oct 25

PMID 17957189

Citations 747

Authors

Julio A Aguirre-Ghiso

Affiliations

Soon will be listed here.

Abstract

Patients with cancer can develop recurrent metastatic disease with latency periods that range from years even to decades. This pause can be explained by cancer dormancy, a stage in cancer progression in which residual disease is present but remains asymptomatic. Cancer dormancy is poorly understood, resulting in major shortcomings in our understanding of the full complexity of the disease. Here, I review experimental and clinical evidence that supports the existence of various mechanisms of cancer dormancy including angiogenic dormancy, cellular dormancy (G0-G1 arrest) and immunosurveillance. The advances in this field provide an emerging picture of how cancer dormancy can ensue and how it could be therapeutically targeted.

Citing Articles

TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma.

Chen S, Zhang X, Basappa B, Zhu T, Pandey V, Lobie P Commun Med (Lond). 2025; 5(1):45.

PMID: 39984660 PMC: 11845601. DOI: 10.1038/s43856-024-00710-9.

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies.

Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K Mol Cancer. 2025; 24(1):47.

PMID: 39953555 PMC: 11829473. DOI: 10.1186/s12943-025-02250-9.

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.

Autophagy induced by metabolic processes leads to solid tumor cell metastatic dormancy and recurrence.

Ferdousmakan S, Mansourian D, Seyedi Asl F, Fathi Z, Maleki-Sheikhabadi F, Nabi Afjadi M Med Oncol. 2025; 42(3):62.

PMID: 39899220 DOI: 10.1007/s12032-025-02607-6.

References

Okajima E, Thorgeirsson U . Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem Biophys Res Commun. 2000; 270(1):108-11. DOI: 10.1006/bbrc.2000.2386. View

Rinker-Schaeffer C, OKeefe J, Welch D, Theodorescu D . Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res. 2006; 12(13):3882-9. PMC: 1525213. DOI: 10.1158/1078-0432.CCR-06-1014. View

Farrar J, KATZ K, Windsor J, Thrush G, Scheuermann R, UHR J . Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol. 1999; 162(5):2842-9. View

Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C . Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007; 448(7151):375-9. DOI: 10.1038/nature05949. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

White D, Kurpios N, Zuo D, Hassell J, Blaess S, Mueller U . Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 2004; 6(2):159-70. DOI: 10.1016/j.ccr.2004.06.025. View

Cheung I, Feng Y, Vickers A, Gerald W, Cheung N . Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn. 2007; 9(2):237-41. PMC: 1867438. DOI: 10.2353/jmoldx.2007.060130. View

Kienle P, Koch M . Minimal residual disease in gastrointestinal cancer. Semin Surg Oncol. 2001; 20(4):282-93. DOI: 10.1002/ssu.1046. View

Hickson J, Huo D, Vander Griend D, Lin A, Rinker-Schaeffer C, Yamada S . The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006; 66(4):2264-70. DOI: 10.1158/0008-5472.CAN-05-3676. View

10.

Weinhold K, Miller D, Wheelock E . The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. J Exp Med. 1979; 149(3):745-57. PMC: 2184829. DOI: 10.1084/jem.149.3.745. View

11.

Larsson O, Zetterberg A, Engstrom W . Cell-cycle-specific induction of quiescence achieved by limited inhibition of protein synthesis: counteractive effect of addition of purified growth factors. J Cell Sci. 1985; 73:375-87. DOI: 10.1242/jcs.73.1.375. View

12.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

13.

Coller H, Sang L, Roberts J . A new description of cellular quiescence. PLoS Biol. 2006; 4(3):e83. PMC: 1393757. DOI: 10.1371/journal.pbio.0040083. View

14.

Merlo L, Pepper J, Reid B, Maley C . Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006; 6(12):924-35. DOI: 10.1038/nrc2013. View

15.

Blaheta H, Paul T, Sotlar K, Maczey E, Schittek B, Paul A . Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br J Dermatol. 2001; 145(2):195-202. DOI: 10.1046/j.1365-2133.2001.04334.x. View

16.

Saudemont A, Quesnel B . In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood. 2004; 104(7):2124-33. DOI: 10.1182/blood-2004-01-0064. View

17.

Weinhold K, Goldstein L, Wheelock E . The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J Exp Med. 1979; 149(3):732-44. PMC: 2184833. DOI: 10.1084/jem.149.3.732. View

18.

Park Y, Zhao X, Lesueur F, Lowy D, Lancaster M, Pharoah P . Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005; 37(10):1055-62. PMC: 2140048. DOI: 10.1038/ng1635. View

19.

Kovacs A, Ghahremani M, Stefenelli U, Bitter K . Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results. J Chemother. 2003; 15(5):495-502. DOI: 10.1179/joc.2003.15.5.495. View

20.

Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B . uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A. 2006; 103(46):17361-5. PMC: 1838539. DOI: 10.1073/pnas.0608113103. View